
    
      This is a single-center, interventional, single-arm, open-label, two-cohort clinical trial. A
      total of 20 patients will be enrolled (10 with NBCCS-associated KCOT and 10 with sporadic
      KCOT) over a period of 2 years. This is a 3 year study where each patient will undergo up to
      1 year of treatment and up to 2 years of post-treatment follow-up.

      All patients will be assessed for safety and efficacy of the study drug GDC-0449
      (Vismodegib).
    
  